• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gold Rises 1%; Accenture Shares Surge After Q3 Results

    6/20/24 12:00:55 PM ET
    $ACN
    $FEMY
    $MGOL
    $SONN
    Real Estate
    Real Estate
    Medical/Dental Instruments
    Health Care
    Get the next $ACN alert in real time by email

    U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining over 50 points on Thursday.

    Following the market opening Thursday, the Dow traded up 0.17% to 38,898.96 while the NASDAQ rose 0.01% to 17,864.13. The S&P 500 also rose, gaining, 0.09% to 5,491.81.

    Check This Out: Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday

    Leading and Lagging Sectors

    Energy shares jumped by 1.5% on Thursday.

    In trading on Thursday, real estate shares fell by 0.2%.

    Top Headline

    Shares of Accenture Plc (NYSE:ACN) gained around 7% during Thursday's session after the company reported third-quarter fiscal 2024 results.

    The company posted sales of $16.47 billion compared with the analyst consensus of $16.55 billion, down 1% Y/Y in U.S. dollars and up by 1.4% in local currency.  Revenues were slightly above the midpoint of the company's guided range of $16.10 billion – $16.70 billion. Adjusted EPS of $3.13 missed the analyst consensus of $3.15.

    Accenture expects fourth-quarter revenues of $16.05 billion – $16.65 billion (versus consensus of $16.56 billion).

    Equities Trading UP
                           

    • MGO Global, Inc. (NASDAQ:MGOL) shares shot up 154% to $1.1672 after the company said it expects the pending acquisition of Spetner Associates to close in the second half of 2024, projecting it to increase annualized revenue to approximately $28 million.
    • Shares of Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) got a boost, surging 147% to $3.42 after the company said it expects first customer deliveries of the i300 in the fourth quarter and anticipates selling over 5,000 units in the fiscal year ending Sept. 30, 2025.
    • Femasys Inc. (NASDAQ:FEMY) shares were also up, gaining 23% to $1.17 after receiving CE Mark approval from the EU MDR for its FemaSeed, FemVue, FemCerv, and FemCath products.

    Equities Trading DOWN

    • Tempest Therapeutics, Inc. (NASDAQ:TPST) shares dropped 27% to $2.0847 after the company announced new data from the ongoing Phase 1b/2 clinical study on amezalpat2 (TPST-1120).
    • Shares of Trevena, Inc. (NASDAQ:TRVN) were down 37% to $0.226. Trevena announced preclinical TRV045 data for long-term analgestic effect in prelinical model of neuropathic pain. Also, the company announced TRV045 results provided director for additional NIH-initiated studies in epilepsy prevention and treatment.
    • Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) was down, falling 29% to $1.10. Sonnet BioTherapeutics announced exercise of warrants for gross proceeds of $3.4 million.

    Also Check This Out: Top 4 Financial Stocks That Could Lead To Your Biggest Gains In Q2

    Commodities

    In commodity news, oil traded up 0.9% to $82.34 while gold traded up 1.1% at $2,371.90.

    Silver traded up 3.8% to $30.69 on Thursday, while copper rose 1.9% to $4.5755.

    Euro zone

    European shares were higher today. The eurozone's STOXX 600 gained 0.67%, Germany's DAX rose 0.73% and France's CAC 40 gained 1.14%. Spain's IBEX 35 Index rose 0.96%, while London's FTSE 100 climbed 0.72%.

    The Bank of England held the Bank Rate at 5.25% during its recent meeting, as projected. Producer prices in Germany fell by 2.2% year-over-year in May compared to a 3.3% decline in the earlier month.

    Passenger car registrations in the European Union fell 3.0% year-over-year to a three-month low level of 911.7 thousand units in May.

    Asia Pacific Markets

    Asian markets closed mixed on Thursday, with Japan's Nikkei gaining 0.16%, Hong Kong's Hang Seng Index declining 0.52%, China's Shanghai Composite Index falling 0.42% and India's S&P BSE Sensex gaining 0.18%.

    The People’s Bank of China maintained key lending rates at the June fixing. Hong Kong's unemployment rate came in unchanged at 3% during the three months ending May. Singapore's unemployment rate increased to 2.1% in the first quarter of 2024 versus 2.0% in the prior period.

    Economics

    • The U.S. current account deficit rose by $15.8 billion to $237.6 billion during the first quarter, and versus market estimates of a $206.4 billion gap.
    • The Philadelphia Fed Manufacturing Index fell 3.2 points to a reading of 1.3 in June, missing market expectations of 5.
    • U.S. initial jobless claims fell by 5,000 to 238,000 in the second week of June, compared to market estimates of 235,000.
    • Housing starts in declined 5.5% to an annualized rate of 1.277 million in May, while building permits fell by 3.8% to an annual rate of 1.386 million.

    Now Read This: How To Earn $500 A Month From Smith & Wesson Brands Stock Ahead Of Q4 Earnings

    Get the next $ACN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACN
    $FEMY
    $MGOL
    $SONN

    CompanyDatePrice TargetRatingAnalyst
    Accenture plc
    $ACN
    2/17/2026$275.00Equal Weight → Overweight
    Wells Fargo
    Accenture plc
    $ACN
    1/22/2026$313.00Buy
    Berenberg
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    Accenture plc
    $ACN
    1/6/2026$317.00Buy
    Truist
    Accenture plc
    $ACN
    12/16/2025$320.00Equal-Weight → Overweight
    Morgan Stanley
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    Accenture plc
    $ACN
    10/23/2025$266.00Neutral
    Citigroup
    Accenture plc
    $ACN
    10/22/2025$251.00Equal Weight
    Wells Fargo
    More analyst ratings

    $ACN
    $FEMY
    $MGOL
    $SONN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Accenture upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Accenture from Equal Weight to Overweight and set a new price target of $275.00

    2/17/26 8:01:23 AM ET
    $ACN
    Real Estate

    Berenberg initiated coverage on Accenture with a new price target

    Berenberg initiated coverage of Accenture with a rating of Buy and set a new price target of $313.00

    1/22/26 8:28:24 AM ET
    $ACN
    Real Estate

    Tempest Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Tempest Therapeutics from Neutral to Buy and set a new price target of $11.00

    1/22/26 8:24:05 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACN
    $FEMY
    $MGOL
    $SONN
    SEC Filings

    View All

    Tempest Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    2/11/26 7:14:04 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Changes in Control of Registrant

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    2/6/26 4:12:27 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Accenture plc

    S-8 - Accenture plc (0001467373) (Filer)

    2/4/26 4:15:43 PM ET
    $ACN
    Real Estate

    $ACN
    $FEMY
    $MGOL
    $SONN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Accenture Appoints Rachel Frey Chief Communications Officer

    Accenture (NYSE:ACN) today announced the appointment of Rachel Frey as chief communications officer, a newly created role. Effective immediately, Frey reports to Accenture Chair and CEO Julie Sweet and joins Accenture's Global Management Committee. Frey brings more than two decades of experience in communications. In her most recent role as Accenture's global head of Corporate Communications, she strengthened the company's relationships with external audiences; developed and elevated an enhanced earned communications strategy that has strategically positioned Accenture and its leaders at the forefront of AI reinvention across every major sector and region around the world; and leveraged d

    2/11/26 10:43:00 AM ET
    $ACN
    Real Estate

    Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

    Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assetsDevelopment approach prioritizes partner-funded and externally supported programs to generate clinical data before deploying significant internal capitalPipeline expansion includes TPST-4003, an in vivo dual-targeting CD19/BCMA CAR-T, with potential near-term milestones BRISBANE, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a diversified portfolio of cell therapy and small molecule product candidates, today outlined its post-transaction strategy to advan

    2/11/26 6:59:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Accenture Federal Services Selected to Support the Mission-Critical Modernization of Veteran Health Records for the Department of Veterans Affairs

    Accenture Federal Services, a subsidiary of Accenture (NYSE:ACN), has been selected to support the U.S. Department of Veterans Affairs (VA) Electronic Health Record Modernization (EHRM) program. This innovative 4.5-year contract marks a pivotal milestone in VA's mission to transform healthcare delivery for more than 9 million Veterans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204089246/en/ The EHRM program is a critical and strategic initiative to replace legacy systems with the modern, integrated Oracle Health Electronic Health Record (EHR) system. This transition is designed to create a single, seamless, and secure li

    2/5/26 7:36:00 AM ET
    $ACN
    Real Estate

    $ACN
    $FEMY
    $MGOL
    $SONN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Lee-Sepsick Kathy

    4 - FEMASYS INC (0001339005) (Issuer)

    2/20/26 5:37:51 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Elefant Dov

    4 - FEMASYS INC (0001339005) (Issuer)

    2/20/26 5:32:25 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Technology Officer Sipos Jeremy Alexander

    4 - FEMASYS INC (0001339005) (Issuer)

    2/17/26 5:47:34 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $ACN
    $FEMY
    $MGOL
    $SONN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Brady Stephen R bought $73,850 worth of shares (35,000 units at $2.11), increasing direct ownership by 308% to 46,376 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/8/24 4:15:11 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Whiting Samuel bought $9,951 worth of shares (4,672 units at $2.13), increasing direct ownership by 95% to 9,573 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/3/24 7:35:42 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corporate Controller Trojanowski Justin bought $16,200 worth of shares (7,500 units at $2.16), increasing direct ownership by 51% to 22,168 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/2/24 4:15:14 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACN
    $FEMY
    $MGOL
    $SONN
    Leadership Updates

    Live Leadership Updates

    View All

    Accenture Appoints Rachel Frey Chief Communications Officer

    Accenture (NYSE:ACN) today announced the appointment of Rachel Frey as chief communications officer, a newly created role. Effective immediately, Frey reports to Accenture Chair and CEO Julie Sweet and joins Accenture's Global Management Committee. Frey brings more than two decades of experience in communications. In her most recent role as Accenture's global head of Corporate Communications, she strengthened the company's relationships with external audiences; developed and elevated an enhanced earned communications strategy that has strategically positioned Accenture and its leaders at the forefront of AI reinvention across every major sector and region around the world; and leveraged d

    2/11/26 10:43:00 AM ET
    $ACN
    Real Estate

    Accenture Appoints Shaheen Sayed as Chief Commercial Officer for Reinvention Services

    Matt Prebble to Lead Accenture in UK, Ireland & Africa Accenture (NYSE:ACN) today announced that Shaheen Sayed has been appointed as Chief Commercial Officer of Reinvention Services. In this new role, Shaheen will be responsible for streamlining how Accenture delivers AI-enabled solutions that meet the evolving needs of clients for the AI era. She will play a critical role in integrating capabilities to drive sustainable growth and long-term client value. Shaheen will continue to be a member of the Global Management Committee. She will be succeeded in her role as lead for Accenture in the UK, Ireland & Africa (UKIA) by Matt Prebble, who currently serves as Data & AI lead for EMEA. Matt

    10/2/25 8:59:00 AM ET
    $ACN
    Real Estate

    Accenture Acquires Identity and Access Management Company IAMConcepts to Expand Cybersecurity Footprint in Canada

    Acquisition brings Accenture highly specialized, credentialed talent and enhances industry solutions Accenture (NYSE:ACN) has acquired IAMConcepts, a privately held Canadian company specializing in identity and access management (IAM) services. The acquisition will bolster Accenture's ability to deliver advanced IAM solutions in Canada across key critical infrastructure industries such as financial services, power utilities, mining and transportation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908044917/en/Accenture has acquired IAMConcepts, a privately held Canadian company specializing in identity and access managemen

    9/9/25 11:22:00 AM ET
    $ACN
    Real Estate

    $ACN
    $FEMY
    $MGOL
    $SONN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Trevena Inc.

    SC 13G/A - TREVENA INC (0001429560) (Subject)

    11/14/24 4:43:11 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Trevena Inc.

    SC 13G - TREVENA INC (0001429560) (Subject)

    9/19/24 4:09:55 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tempest Therapeutics Inc.

    SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

    8/12/24 8:59:00 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACN
    $FEMY
    $MGOL
    $SONN
    Financials

    Live finance-specific insights

    View All

    Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

    BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the "Record Date") for the distribution of warrants to purchase Tempest common stock ("Warrants") as a dividend (the "Warrant Dividends"), as contemplated by Tempest's previously announced Asset Purchase Agreement (the "Asset Purchase Agreement") with Erigen LLC and Factor Bioscience Inc. The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of c

    1/20/26 5:20:02 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Accenture Reports First-Quarter Fiscal 2026 Results

    Accenture delivers strong new bookings and revenue growth at the top of the company's guided range, with strong profitability and free cash flow; Confirms outlook for fiscal 2026 revenue growth, and adjusted operating margin and EPS Accenture (NYSE:ACN) reported financial results for the first quarter of fiscal 2026 ended November 30, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218755982/en/ All comparisons are to the first quarter of fiscal 2025, unless noted otherwise. Accenture Chair and CEO Julie Sweet "I am very pleased with our $21 billion in new bookings, including 33 clients with quarterly bookings greater t

    12/18/25 6:39:00 AM ET
    $ACN
    Real Estate

    Accenture to Announce First-Quarter Fiscal 2026 Results

    Accenture Schedules First-Quarter Fiscal 2026 Earnings Call Accenture (NYSE:ACN) will host a conference call at 8:00 a.m. EST on Thursday, December 18, 2025, to discuss its first-quarter fiscal 2026 financial results. An earnings news release will be issued before the call. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202782467/en/ To participate in the teleconference, please dial +1 (877) 883-0383 [+1 (412) 317-6061 outside the U.S., Puerto Rico and Canada] and enter access code 1422495 approximately 15 minutes before the scheduled start of the call. The conference call will also be accessible live via webcast on the Inve

    12/2/25 6:59:00 AM ET
    $ACN
    Real Estate